News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase I
Sunesis (SNSS) Release: Biotech Announces Clinical And Regulatory Updates To SNS-062 And Vosaroxin Programs 1/23/2017
Resverlogix (RVX.TO) Release: Company Provides Groundbreaking Results In Patients With Severe Kidney Impairments 1/23/2017
Theravance Biopharma (TBPH) Release: Company Reports New Data From Ongoing TOUR Observational Patient Registry In Oral Presentation At SCCM Critical Care Congress 1/23/2017
GeoVax Labs Inc. (GOVX.OB) Release: Pharma Announces Initiation Of HIV Human Clinical Trial 1/23/2017
NantKwest Release: Landmark First-In-Human Clinical Study Launch Using A Genetically Engineered Natural Killer Cell For The Treatment Of Cancer 1/23/2017
OncoMed (OMED) Release: Company Initiates Enrollment Of Phase Ib Clinical Trial Of Brontictuzumab For The Treatment Of Metastatic Colorectal Cancer Patients 1/20/2017
ARMO BioSciences Release: Company Presents New Phase Ib Clinical Data For AM0010 In Advanced Pancreatic Cancer Patients At 2017 Gastrointestinal Cancers Symposium 1/20/2017
Infinity Pharma (INFI) Release: Company Presents Preclinical Data And Phase 1 Clinical Data On IPI-549 At PI3K Keystone Symposia Conference 1/20/2017
Abeona Therapeutics Release: Company Receives Orphan Drug Designation In The European Union For ABO-101 Gene Therapy In Sanfilippo Syndrome Type B 1/19/2017
Catabasis (CATB) Release: Company's Phase I Data On Edasalonexent (CAT-1004), A Potential Disease-Modifying Therapy Being Developed For Duchenne Muscular Dystrophy, Published In The Journal Of Clinical Pharmacology 1/19/2017
BioTime (BTX) Release: Additional Data From Company’s OpRegen Clinical Trial in Dry-AMD to be Presented At ARVO 2017 1/19/2017
Swedish Orphan Biovitrum Release: First Patients Enrolled In 24 Month Real-World Study Evaluating Effectiveness Of Elocta 1/19/2017
Lysogene Release: Biotech Receives Rare Pediatric Disease Designation From FDA For LYS-GM101 For Treatment Of GM1 Gangliosidosis 1/18/2017
WuXi AppTec Release: Novel Anti-IL-6 Antibody For Rheumatoid Arthritis From WuXi-MedImmune (AZN) Joint Venture Receives Clinical Trial Permit (CTP) From CFDA 1/18/2017
aTyr Pharma Release: FDA Grants Fast Track Designation For Company's Resolaris To Treat Limb Girdle Muscular Dystrophy 2B And Removes Partial Clinical Hold For Resolaris 1/18/2017
Daiichi Sankyo Release: Company Initiates Phase 1/2 Study Of Novel Antibody Drug Conjugate U3-1402 In Patients With HER3-Positive Metastatic Or Unresectable Breast Cancer 1/18/2017
Panacea Pharmaceuticals, Inc. Release: Company Initiates Phase I Study Of First-In-Class Cancer Vaccine Therapy Candidate In Patients With Persistent Prostate Cancer 1/17/2017
ProtoKinetix Inc. (PKTX.OB) Release: Company Announces Investigator Sponsored Clinical Trial Submitted To Health Canada For The Use Of AAGP In The Treatment Of Type 1 Diabetes 1/17/2017
JPM17: Why the Key to Gene Therapy Could be in an Old Bay Area Warehouse 1/16/2017
Hutchison China MediTech (Chi-Med) Release: Company Presents Phase I/II Clinical Data For Selective VEGFR Inhibitor Fruquintinib At The 2017 Gastrointestinal Cancers Symposium 1/16/2017
ObsEva Release: Company Announces Completion Of Phase I First-In-Women Study Of OBE022 For The Treatment Of Preterm Labor 1/13/2017
Celyad Release: Biotech Announces Registration Of The First Pancreatic Cancer Patient In Its CAR-T NKR-2THINK Trial In Belgium 1/12/2017
JPM17: Secretive Moderna Finally Unveils Pipeline, Financials 1/11/2017
Sangamo (SGMO) Release: Pharma Receives Orphan Drug Designation From The FDA For SB-318 Genome Editing Treatment For MPS I 1/11/2017
Bird Rock Bio Release: Biopharma Receives Approval To Start First In Human Clinical Trial For Namacizumab, Enters Into Agreement With GE Healthcare For Process Development And Scale-Up To Provide Clinical Phase 2 Cgmp Material, And Enters Into A Collaboration And Option Agreement With Janssen Pharmaceutical 1/11/2017
Affimed (AFMD) Release: Biopharma Provides Update On NK-Cell Immuno-Oncology Platform 1/11/2017
Corvus Pharma Announces Expansion Of Renal Cell Carcinoma Cohort In Ongoing Phase I/Ib Clinical Study Of Lead Checkpoint Inhibitor CPI-444 1/10/2017
ViraCyte Release: Pharma Granted U.S. FDA Fast Track Designation For Viralym-C 1/10/2017
Sangamo (SGMO) Release: Company Presents Latest Advances In Zinc Finger Nuclease Platform Technology At Keystone Symposium On Precision Genome Engineering 1/10/2017
Mologen (MOLGF.PK) Release: Grant To Collaboration Partner For Combination Study In HIV With Lead Product Lefitolimod 1/10/2017
Hutchison China MediTech (Chi-Med) Release: Company Initiates HMPL-523 Clinical Trials In Hematological Cancer In China 1/10/2017
BioMarin (BMRN) Release: Bay Area Biotech Solidifies Status as Top Dog in Hemophilia A Gene Therapy 1/10/2017
Sierra Oncology Successfully Transfers Sponsorship Of SRA737 Clinical Trials 1/9/2017
MabVax Therapeutics Files Investigational New Drug Application For Novel Radioimmunotherapy Agent MVT-1075 1/9/2017
Lexicon Pharma (LXRX) Begins Phase 1 Clinical Trial Of Locally-Acting SGLT1 Inhibitor, LX2761, For Potential Treatment Of Diabetes 1/9/2017
NeuroGenetic Pharmaceuticals, Inc. Completes Phase 1 Clinical Trials For NGP 555 To Treat And Prevent Alzheimer’s Disease; Shown As Safe And Well-Tolerated In Healthy Volunteers 1/9/2017
Tricida Announces Positive Topline Phase I/II Clinical Trial Results For TRC101 In 135 Subjects With Chronic Kidney Disease And Metabolic Acidosis 1/9/2017
Aridis Pharma Reports Positive Clinical Data From Phase 1/2a Study Of Human Monoclonal Antibody AR-301 For Treating Pneumonia 1/6/2017
CalciMedica Initiates Phase 1 Clinical Studies For CRAC Channel Inhibitor 1/6/2017
MacroGenics (MGNX)’ MGD006 Granted Orphan Drug Status For AML By FDA 1/6/2017
Chimerix (CMRX) Announces Preliminary Data From Ongoing Phase I Dose Escalation Study Of Intravenous Brincidofovir In Healthy Subjects 1/6/2017
Mirati Therapeutics  (MRTX) Provides Update On Glesatinib And Sitravatinib Clinical Trials And Pipeline Programs 1/6/2017
RedHill Biopharma (RDHL) Announces YELIVA (ABC294640) Abstract Presentation At The 2017 Cholangiocarcinoma Foundation Annual Conference 1/6/2017
Rgenix Announces Treatment Of First Patient In Phase 1 Trial Of RGX-104, Its Lead Immuno-Oncology Therapeutic 1/6/2017
TARIS Biomedical Announces Positive Results From Ph1b Trial Of TAR-200 (Gemristm) In Patients With Muscle Invasive Bladder Cancer 1/6/2017
Janssen Biotech (JNJ) Enters Immunotherapy Clinical Collaboration With Bristol-Myers Squibb (BMY) To Evaluate Daratumumab (DARZALEX) In Combination With Nivolumab (OPDIVO) 1/5/2017
Fibrocell (FCSC) Announces FDA Fast Track Designation Of FCX-007 For Treatment Of Recessive Dystrophic Epidermolysis Bullosa 1/5/2017
Fate Therapeutics (FATE) Announces First Patient Treated In Protmune PROTECT Clinical Trial For The Prevention Of Graft-Versus-Host Disease 1/5/2017
Zosano (ZSAN) Announces Last Subject Treated In Its Migraine Pivotal Trial 1/5/2017
Enterome Starts Phase I Clinical Trial With Its Lead Candidate EB8018 To Treat Crohn's Disease 1/5/2017
Seattle Genetics (SGEN) Initiates Phase I Trial Of SGN-CD352A For Patients With Relapsed Or Refractory Multiple Myeloma 1/5/2017
Minervax Announces Positive Results From Phase I Trial In 240 Healthy Adult Women With Its Innovative Group B Streptococcal (GBS) Vaccine To Prevent Life-Threatening Infections In Newborns 1/5/2017
Lycera Announces Initiation Of Phase 1/2a Study ARGON Of Immuno-Oncology Candidate LYC-55716 In Patients With Advanced Solid Tumors 1/4/2017
Rebiotix Treats First Patient In Phase 1 Study Of RBX7455, An Orally Delivered Broad-Spectrum Non-Frozen Microbiota Capsule For Recurrent Clostridium Difficile Infection 1/4/2017
OncoMed (OMED) Initiates Enrollment Of Phase Ib Clinical Trial Of Anti-DLL4/VEGF Bispecific Antibody As Second-Line Treatment For Metastatic Colorectal Cancer Patients 1/4/2017
Kura Oncology Receives FDA Clearance To Proceed With Clinical Trial For ERK Inhibitor KO-947 And Nominates KO-539 As Development Candidate For Menin-MLL Inhibitor Program 1/4/2017
Adamas Pharma (ADMS) Completes Phase I Clinical Trial Of ADS-4101 For Treatment Of Partial Onset Seizures In Patients With Epilepsy 1/4/2017
FDA Grants Fast Track Designation To Enanta Pharmaceuticals, Inc.’s FXR Agonist Candidate, EDP-305, For The Treatment Of NASH With Liver Fibrosis 1/4/2017
Asana Biosciences Announces Dosing Of First Patient In Phase I Trial Of ASN003, A Novel And Highly Selective B-RAF/PI3 Kinase Inhibitor 1/4/2017
Renowned Sinus Surgeon Dr. Peter-John Wormald Comments On AmpliPhi Bio (APHB)’ Favorable Phase I Results Of AB-SA01 In Chronic Rhinosinusitis Patients 1/4/2017
Glenmark Pharma Receives FDA Clearance Of IND For GBR 1302-BEAT Phase I Trial 1/3/2017
Ensysce Biosciences Inc. To Present Initial Phase 1 Data On Abuse Deterrent Opioid, PF614, At Biotech Showcase 2017 1/3/2017
4 Fatal Deaths in Seattle Genetics (SGEN)' Early-Stage Trials of AML Drug 12/30/2016
Fortress Biotech (FBIO) Surged After Reporting Big Success With CAR-T Cancer Approach 12/30/2016
Incyte (INCY) Announces First Patient Treated in Pivotal Clinical Trial Program for Ruxolitinib (Jakafi®) in Graft-versus-Host Disease 12/30/2016
Prima Biomed (PRR.AX) Announces First Clinical Data From Combination Of IMP321 With Anti-PD1 12/29/2016
ImmunoGen (IMGN) Announces Mirvetuximab Soravtansine Phase 1 Expansion Cohort Results In Platinum-Resistant Ovarian Cancer Published In The Journal Of Clinical Oncology 12/28/2016
BeiGene (BGNE) Doses First Patient In China Phase I PARP Trial 12/27/2016
Biohaven Enrolls First Patient In Pivotal Trial Of BHV-4157 In Patients With Hereditary Spinocerebellar Ataxia 12/22/2016
Provectus Announces Two Poster Presentations On PV-10 For Liver Tumors 12/22/2016
Bay Area’s CBT Pharma Plans to Launch 2 Phase I Trials in 2017 12/22/2016
Inovio Pharma (INO)’s Zika Vaccine Generates Robust Immune Responses In First Human Study 12/21/2016
Apellis Pharma Announces FDA Fast Track Designation For APL-2 In PNH 12/20/2016
MeiraGTx Granted Orphan Drug Designation For Its A004 Gene Therapy Treatment For Retinitis Pigmentosa 12/20/2016
AmpliPhi Bio (APHB) Reports Favorable Final Results From Phase 1 Trial Of AB-SA01 In Chronic Rhinosinusitis Patients 12/20/2016
Juno (JUNO)’ And Celgene (CELG)’s Investigational Drug JCAR017 Granted Breakthrough Therapy Designation From FDA And Priority Medicines Eligibility From EMAFor Relapsed/Refractory Diffuse Large B-Cell Lymphoma 12/20/2016
Astellas (ALPMY) Announces FDA Fast Track Designation For ASP0892, DNA Vaccine For Mitigation Of Severe Hypersensitivity Reactions Due To Peanut Allergy 12/20/2016
Tetra Discovery Partners Announces Positive Results From Phase 1 Studies Of Cognition Drug Candidate, BPN14770 12/19/2016
AmpliPhi Bio (APHB) Reports Favorable Final Results From Phase 1 Trial Of AB-SA01 In Chronic Rhinosinusitis Patients 12/19/2016
Spero Initiates First Clinical Study Of Lead Potentiator Candidate For The Treatment Of Multidrug Resistant Gram-Negative Infections 12/19/2016
Poxel SAS Announces Phase 1 Initiation Of EYP001 For The Treatment Of Chronic Hepatitis B Virus Infection By Licensing Partner Enyo Pharma 12/19/2016
DRGT's Novel Celecoxib Composition - Opportunity For Low Dose, Immediate Onset Of Pain Relief With The Only NSAID COX-2 Inhibitor On The Market 12/19/2016
New York’s Cellectis (ALCLS) Looks to 2017 for Clinical Trials of AML Treatment 12/16/2016
Enyo Pharma Announces Successful Initiation Of The Phase 1 Clinical Programme With EYP001, Its Lead Candidate For The Treatment Of Chronic Hepatitis B Virus Infection 12/16/2016
Alnylam (ALNY) Presents Initial 2017 Pipeline Goals At R&D Day With Focus On Alnylam 2020 Strategy 12/16/2016
Cellectis (ALCLS) Announces Recombinant DNA Advisory Committee’s (RAC) Unanimous Approval Of UCART123 Phase 1 Study Protocols In AML And BPDCN 12/16/2016
Investors Sigh With Relief as Biogen (BIIB)'s Alzheimer's Drug Delivers in Early-Stage Study 12/15/2016
BioPharm Executive: So Long 2016 (and Good Riddance?) 12/14/2016
Abide Therapeutics Announces First Patient Dosed In Phase 1b Study To Assess The Effect Of ABX-1431 In Patients With Functional Dyspepsia 12/14/2016
CytomX Announces U.S. FDA Clearance Of Investigational New Drug Application For Phase I/II Clinical Study Of Anti-PD-L1 Probody Therapeutic, CX-072 12/14/2016
Minoryx Therapeutics Receives European Orphan Drug Designation For Its Lead Candidate MIN-102 12/14/2016
Concert Pharmaceuticals, Inc. (CNCE) Announces CTP-543 Positive Top-Line Phase 1 Results 12/14/2016
SpinalCyte, LLC Receives Institutional Review Board Approval For Phase I Clinical Trial 12/14/2016
Zenith Epigentics Announces Initiation Of Phase 1b Clinical Combination Trial For ZEN-3694 12/14/2016
Addex Therapeutics (ADXN.SW) ADX71441 Pharmacological Profile Published In Neuropharmacology 12/13/2016
aTyr Pharma Reports Promising Signals Of Clinical Activity In Multiple Rare Genetically Distinct Myopathies With Resolaris In Exploratory Trials 12/13/2016
SCYNEXIS, Inc. (SCYX) Achieves New Development Milestones Reinforcing The Versatility Of SCY-078 In Treating Serious Fungal Infections 12/13/2016
Vyome Presents On The Development Of The Dual Action Rational Therapeutics Platform At The 2016 American Society of Microbiology Conference On Antibacterial Development 12/13/2016
3 Drugs Heading To The FDA Soon 12/12/2016
Eisai Inc. (ESALF.PK) Presents Data On BACE Inhibitor Elenbecestat (E2609) At 9th Clinical Trials On Alzheimer's Disease (CTAD) Meeting 12/12/2016
Tyme Completes The First Phase Of Its Prostate Cancer Clinical Study 12/12/2016
Edge Therapeutics Announces Publication Of Phase I/II Data On EG-1962 For The Treatment Of Aneurysmal Subarachnoid Hemorrhage In Peer-Reviewed Medical Journal, Stroke 12/12/2016
Cancer Targeted Technology Commences Phase I Clinical Trial Of CTT1057, A Diagnostic Imaging Agent For Prostate Cancer 12/12/2016
Seattle Genetics (SGEN) Highlights Phase 1 Data For Novel Antibody-Drug Conjugate SGN-LIV1A In Patients With Metastatic Breast Cancer At San Antonio Breast Cancer Symposium 12/12/2016
AXON Neuroscience’s Alzheimer Tau Vaccine Phase 1 Study Results Published In Lancet Neurology 12/12/2016
All Eyes Will Be on Biogen (BIIB) and Its Much-Anticipated Alzheimer's Data Tomorrow 12/9/2016
C2N Reports Phase I Study Results Of C2N-8E12 (ABBV-8E12) – Anti-Tau Antibody – In Subjects With Progressive Supranuclear Palsy 12/9/2016
3 Biotechs That Could Peak in 2017 12/9/2016
MRI Interventions (MRIC)’ Clearpoint Neuro Navigation System Utilized In Voyager Therapeutics (VYGR)’ VY-AADC01 Phase Ib Trial; Positive Interim Results Reported 12/8/2016
Radius Health (RDUS) Presents Positive Phase I Data For Investigational Drug RAD1901 At The San Antonio Breast Cancer Symposium (SABCS) 2016 12/8/2016
Van Andel Institute Release: Diabetes Drug Slows Experimental Parkinson's Disease Progression, Human Trials To Begin Next Year 12/8/2016
Avelas Biosciences Presents Phase 1b Clinical Trial Data For AVB-620 At 2016 San Antonio Breast Cancer Symposium 12/8/2016
Vyome Presents On Development Of Dual Action Rational Therapeutics (Darts) To Treat Infections Caused By Antibiotic-Resistant Skin Opportunist Pathogens At Re-Entering Antibacterial Discovery And Development Summit 2016 12/8/2016
NantHealth (NH), NantKwest And Nantomics Announce Availability Of GPS Cancer And Phase I – III QUILT Trials Through The U.S. NantKwest’s Clinicaltrials.Gov 12/8/2016
Voyager Therapeutics (VYGR) Soars as Parkinson’s Drug Shines in Early-Stage Trial 12/8/2016
4 Massachusetts Biotechs Making Waves at American Society of Hematology 12/7/2016
Advaxis (ADXS) To Present Data At Imvacs-Immunization And Vaccine Summit On Use Of Detoxified Listeriolysin O (dtLLO) As An Effective Adjuvant In Vaccine Formulations 12/7/2016
Aclaris (ACRS) Initiates Phase I Clinical Trial For ATI-50001, An Investigational JAK Inhibitor, For The Treatment Of Alopecia Totalis And Alopecia Universalis 12/7/2016
Johnson & Johnson (JNJ) Hits Roadblock as Recruitment in Diabetes Drug Study From Hanmi Pharma (128940.KS) is Halted 12/7/2016
Juno (JUNO) Highlights Progress With Best-in-Class Strategy In B-Cell Malignancies At American Society of Hematology 12/7/2016
ALOPEXX Oncology Presents Encouraging Results Of A Phase I Study Of DI-Leu16-IL2 In Relapsed/Refractory NHL At The American Society of Hematology Annual Meeting 12/7/2016
BerGenBio AS Presents Promising Phase I Clinical & Biomarker Data From First In Class Axl Inhibitor BGB324 In AML At American Society of Hematology 2016 12/6/2016
Oncternal Therapeutics' Pipeline Candidates Featured In Presentations At The American Society of Hematology Annual Meeting 12/6/2016
Seattle Genetics (SGEN) Highlights Long-Term Follow-Up Data From ADCETRIS®(Brentuximab Vedotin) In T-Cell Lymphomas At American Society of Hematology Annual Meeting 12/6/2016
Gamida Cell Presents Positive Data From Phase 1/2 Study Of NiCord as A Curative Treatment For Sickle Cell Disease At American Society of Hematology 2016 12/6/2016
H3 Biomedicine Announces Data From Lead Development Program Of H3B-8800 In Pre-Clinical Models Of Hematologic Cancers 12/6/2016
Cornerstone Pharmaceuticals, Inc. Presents Phase I Data On CPI-613 In Acute Myeloid Leukemia (AML) And T-Cell Non-Hodgkin's Lymphoma (T-Cell NHL) At American Society of Hematology 2016 12/6/2016
Senhwa Biosciences CX-4945 Phase I Clinical Trial Results Accepted For Presentation At The 2017 ASCO Gastrointestinal Cancers Symposium 12/6/2016
Oncolytics Biotech Inc. (ONC.TO) Collaborators Present Initial Results From REO 019 Study In Multiple Myeloma Combining REOLYSIN, Bortezomib And Dexamethasone At The American Society of Hematology Annual Meeting 12/6/2016
Cellectar Biosciences  (CLRB) Presents Poster At The 58th Annual Meeting Of The American Society of Hematology 12/6/2016
Heat Biologics Presents Topline HS-110/Nivolumab Combination Lung Cancer Results 12/6/2016
Actinium (ATNM.OB) Highlights Results From Phase I Clinical Trial Of Actimab-A At 58th American Society of Hematology Annual Meeting 12/6/2016
Agios (AGIO) Announces New Clinical Data From Dose-Escalation Portion Of Phase I Trial Of Single Agent AG-120 Showing Durable Molecular Responses In Patients With Advanced Hematologic Malignancies 12/6/2016
Sangamo (SGMO) Presents Hemophilia A Program Data At The 2016 American Society of Hematology Meeting 12/6/2016
Bristol-Myers Squibb (BMY) Release: Opdivo (Nivolumab) Alone Or Combined With Yervoy (Ipilimumab) Shows Encouraging Response And Survival Rates In Recurrent Small Cell Lung Cancer, From Phase I/II Study Checkmate -032 12/6/2016
Kadmon Presents Encouraging Data On Tesevatinib In EGFR-Mutated Non-Small Cell Lung Cancer With Brain Metastases And/Or Leptomeningeal Metastases 12/6/2016
Merck & Co. (MRK) Release: Updated KEYTRUDA (Pembrolizumab) Data In Small Cell Lung Cancer And Mesothelioma Presented At 17th World Conference On Lung Cancer 12/6/2016
Juno (JUNO) Lymphoma Drug Impresses in Early Stage Study, But Fear of Cerebral Edema Looms 12/6/2016
Juno (JUNO) Presents Data From TRANSCEND Study Showing 60% Complete Response In Patients With Relapsed Or Refractory Aggressive CD19+ Non-Hodgkin Lymphoma 12/6/2016
Boston Biomedical Announces First Clinical Data For Investigational WT1 Cancer Peptide Vaccine, DSP-7888, At American Society of Hematology Annual Meeting & Exposition 12/6/2016
Blueprint Medicines (BPMC) Announces Proof-Of-Concept Data From Phase 1 Clinical Trial Of BLU-285 In Patients With Advanced Systemic Mastocytosis 12/5/2016
AbbVie (ABBV) Release: IMBRUVICA (ibrutinib) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5-Year Analysis And Long-Term RESONATE-2 Follow-Up Data At American Society of Hematology 2016 Show Lasting Efficacy 12/5/2016
Akari Therapeutics Announces Corporate Update With New Positive Clinical Data And A New Pipeline Of Tick Derived And Engineered Proteins 12/5/2016
Zynerba (ZYNE) Reports Positive Results For ZYN002 CBD Gel In Phase I Studies At 70th Annual Meeting Of The American Epilepsy Society 12/5/2016
EyeGate Pharma Reports Positive Data From Third Stage Of Phase Ib/IIa Clinical Trial Of EGP-437 In Cataract Surgery Patients 12/5/2016
Celldex (CLDX) Presents Data On CDX-1140, A Novel CD40 Agonist Antibody For Hematologic And Solid Malignancies, At The American Society of Hematology Annual Meeting 12/5/2016
MabVax Therapeutics Expands Phase I Clinical Trial Investigation For Patients With Pancreatic Cancer To Include Honorhealth Research Institute 12/5/2016
Children's Hospital of Philadelphia Release: After One Dose Of Gene Therapy, Hemophilia B Patients Maintain Near-Normal Levels Of Clotting Factor 12/5/2016
Matinas BioPharma Commences Dosing In Phase I Study Of Orally Administered Aminoglycoside Antibiotic MAT2501 12/5/2016
Sunesis (SNSS) Announces Presentation Of Results From Completed Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK Inhibitor SNS-062 At American Society of Hematology Annual Meeting 12/5/2016
Global Blood Therapeutics (GBT) Announces New Long-Term Clinical Data From Ongoing Phase I/II Trial Of GBT440 In Sickle Cell Disease At American Society of Hematology 12/5/2016
AbbVie (ABBV) Release: Favorable Response Rates Suggest Promise Of Ibrutinib (IMBRUVICA) Combination Therapy In Two Common Types Of Non-Hodgkin's Lymphoma 12/5/2016
Juno (JUNO) Shows Off Positive Early Data in Leukemia Patients 12/5/2016
Struggling Alnylam (ALNY) Attempts to Reboot Itself With Promising Hemophilia Data 12/5/2016
Daiichi Sankyo Presents Phase 1 Data For MDM2 Inhibitor DS-3032 In Acute Myeloid Leukemia And Myelodysplastic Syndrome At The 58th Annual Meeting Of The American Society of Hematology 12/5/2016
Children's Hospital of Philadelphia Release: In Clinical Trials, CAR T Cell Immunotherapy Continues To Yield Complete Responses In Children & Young Adults With Relapsed And Refractory Leukemia 12/5/2016
American Society of Hematology Release: Bioengineering Innovations Show Promise For Improving Treatments And Drug Delivery 12/5/2016
Seattle Genetics (SGEN) Highlights Long-Term Follow-Up Data From ADCETRIS® (Brentuximab Vedotin) In T-Cell Lymphomas At American Society of Hematology Annual Meeting 12/5/2016
Alnylam (ALNY) Presents Updated Results From Phase I/II Study Of ALN-CC5 In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) 12/5/2016
AstraZeneca PLC (AZN) Release: Early Data Demonstrate Clinical Activity Of Acalabrutinib In Difficult-To-Treat Chronic Lymphocytic Leukemia 12/5/2016
Seattle Genetics (SGEN) Highlights Phase I Vadastuximab Talirine (SGN-CD33A; 33A) Data Presentations, Including Combination Therapy With HMAs, In Patients With Acute Myeloid Leukemia At American Society of Hematology Annual Meeting 12/5/2016
Merck & Co. (MRK) Release: Updated KEYTRUDA (Pembrolizumab) Findings In Patients With Relapsed Or Refractory Primary Mediastinal Large B-Cell Lymphoma Presented At 58th Annual Meeting Of The American Society of Hematology 12/5/2016
Mersana Presents Updated Data On Investigational Cancer Antibody Drug Conjugate At World Conference On Lung Cancer 12/5/2016
Bristol-Myers Squibb (BMY) Release: Encouraging Survival Observed With Opdivo (Nivolumab) Plus Yervoy(Ipilimumab) With Longer Follow-Up In First-Line Advanced Non-Small Cell Lung Cancer, In Updated Phase 1b Checkmate -012 Study 12/5/2016
Celltrion Healthcare (068270.KQ) Presents Positive Results For CT-P10, Biosimilar Rituximab Candidate, In Newly Diagnosed Advanced Stage Follicular Lymphoma 12/5/2016
Acetylon Presents Early Phase 1a/1b Results For Citarinostat (ACY-241) In Combination With Pomalyst And Dexamethasone Showing Promising Treatment Responses In Relapsed Or Relapsed-And-Refractory Multiple Myeloma 12/5/2016
Autolus Release: New CAR-T Approach For The Treatment Of T-Cell Lymphomas Presented At The 2016 American Society of Hematology Annual Meeting 12/5/2016
AmpliPhi Bio (APHB) Reports Favorable Final Results From Phase I Trial Of AB-SA01 12/5/2016
Top 7 Jaw-Dropping Pipeline Blowups This Year 12/5/2016
As Rival Juno (JUNO) Falters, Kite Pharma (KITE) Touts New CAR-T Data and Maps Out BLA Submission Plans 12/5/2016
bluebird bio (BLUE), Celgene (CELG)'s Multiple Myeloma CAR-T Drug Shines in Tiny Study 12/2/2016
BerGenBio AS Presents Promising Phase I Clinical & Biomarker Data From First In Class Axl Inhibitor BGB324 In AML At American Society of Hematology 2016 12/2/2016
Apellis Pharma Reports Positive Interim Results From Phase Ib Clinical Trials Of APL-2 In PNH 12/2/2016
NeuroDerm (NDRM) Announces Top-Line Results Of Pilot PK Trial Comparing ND0701 With Commercial Apomorphine 12/2/2016
Acetylon Announces Upcoming Scientific Presentations On The Use Of Selective HDAC Inhibitors In Treating Genetic Blood Disorders And Cancers 12/2/2016
Ensysce Biosciences Inc. Initiates Phase 1 Clinical Trial To Study PF614, BIO-MD Prodrug Of Oxycodone 12/2/2016
Helix Biopharma (TSX:HBP) Accelerates Escalation Of L-DOS47 Dosing In The U.S. Phase I Study 12/2/2016
Sorrento (SRNE)'s TNK Therapeutics Provides Progress Update For Its Anti-CD38 And CD123 CAR-T Programs For Treatment Of Hematological Malignancies 12/1/2016
Cyclacel Pharma (CYCC)’s Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential In Esophageal Cancer And Acute Leukemia 12/1/2016
Cellectar Biosciences  (CLRB) Announces Results From The First Two Cohorts Of Its CLR 131 Phase I Trial: Demonstrates Excellent Efficacy, Overall Survival Benefit, And Progression Free Survival Similar To Or Better Than Recently Approved Therapies 12/1/2016
Global Blood Therapeutics (GBT) Announces Upcoming Investor Webcast To Review GBT440 Data Being Presented At American Society of Hematology That Support Sickle Cell Disease Program 12/1/2016
Arsanis Receives FDA Fast Track Designation For ASN100 For The Prevention Of Staphylococcus Aureus Pneumonia 12/1/2016
Deciphera Reports Encouraging Clinical Results With DCC-2618 In Genetically-Defined Cancers With Drug Resistant Mutations 12/1/2016
ERYtech Pharma Presents New Data On GRASPA’s Mechanism Of Action At American Society of Hematology Annual Meeting 12/1/2016
Cellular Biomedicine Group (CBMG), A China-US Biopharma, Starts China Trial Of CAR-T Immunotherapy 12/1/2016
Ignyta (RXDX) Announces Compelling Phase I/Ib Clinical Data On RXDX-105, Its VEGFR-Sparing RET Inhibitor, At The 2016 EORTC-Ignyta (RXDX)-NCI Annual Meeting 12/1/2016
Blueprint Medicines (BPMC) Announces Proof-Of-Concept Data From Phase 1 Clinical Trial Of BLU-285 In Patients With Advanced Gastrointestinal Stromal Tumors 12/1/2016
MicuRx Pharma Initiates Phase 1 Clinical Trial In U.S. For Novel Antibiotic Agent MRX-4 11/30/2016
Agenus (AGEN) Announces Commencement Of Phase 1/2 Clinical Trial Of Anti-OX40 Checkpoint Antibody INCAGN1949 In Patients With Solid Tumors 11/30/2016
Oramed (ORMP)'s ORMD-0901 (Oral GLP-1 Analog) Found Safe And Well Tolerated In Phase Ib Study 11/29/2016
Blueprint Medicines (BPMC) Announces Proof-Of-Concept Data From Global Phase 1 Clinical Trial Of BLU-554 In Patients With Advanced Hepatocellular Carcinoma 11/29/2016
OncoMed (OMED) Presents Initial First-In-Human Data For Anti-DLL4/VEGF Bispecific And Anti-RSPO3 At The 28th EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium 11/29/2016
Galapagos (GLPG.BR) Initiates Phase 1 Study With Cystic Fibrosis Drug GLPG2737 11/29/2016
MabVax Therapeutics Enrolls First Patients In Expansion Of Phase I Clinical Trial Treating Newly Diagnosed Pancreatic Cancer Patients 11/28/2016
PharmaMar Begins A Phase I Study Of PM1183 In Japan For The Treatment Of Solid Tumors 11/28/2016
OncoPep Announces Initiation Of Phase 1b Clinical Trial Of PVX-410 In Smoldering Multiple Myeloma And Upcoming Presentation Of Positive Results From Phase 1/2a Clinical Trial At American Society of Hematology 11/28/2016
Cidara (CDTX)’s Presentations At American Society of Hematology 2016 To Highlight Potential Role Of Novel Antifungal CD101 In Patients With Hematologic Malignancies 11/28/2016
Nature Cell Receives U.S. FDA Approval For Phase I And II Alzheimer's Clinical Trial 11/28/2016
European Commission (EC) Approves Bristol-Myers Squibb (BMY)'s Opdivo(Nivolumab) For The Treatment Of Adult Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant And Treatment With Brentuximab Vedotin 11/23/2016
NantKwest Announces Landmark Study Published On high affinity haNK Cell Therapy In The Journal Oncotarget 11/23/2016



//-->